CURRENT
ISSUE
1633

The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to include administration of a third dose in persons ≥12 years old (Pfizer/BioNTech) or ≥18 years old (Moderna) who have undergone solid organ transplantation or have a condition that compromises the immune system to a similar extent (see Table 1).1

Immunocompromised persons are more likely than healthy individuals to have an inadequate antibody response to COVID-19 vaccination, breakthrough SARS-CoV-2 infection, and severe COVID-19 requiring hospitalization....  Continue reading

More from Issue 1633
Previous Issue: 1632      September 6, 2021
Coming Soon
Treatment of Onychomycosis
A New Indication for Empagliflozin (Jardiance)
Bamlanivimab and Etesevimab for Post-Exposure Prophylaxis of COVID-19
Trilaciclib (Cosela) to Prevent Myelosuppression in Small Cell Lung Cancer
Search
Donate
Subscribe
Conversation
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
Advance Release
ADVANCE
RELEASE

Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Available influenza vaccines for the 2021-2022 season are listed in Table 2.

Vaccination of all eligible persons can reduce the prevalence of influenza illness and symptoms that might be confused with ... Continue reading

 Tweets